Skip to main content
SpringerLink
Log in

Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The clinical dose of telmisartan necessary for activation of peroxisome proliferator-activated receptor gamma (PPAR-gamma) has not been established. The authors investigated the effect of high-dose telmisartan on serum levels of the high-molecular-weight (HMW) adiponectin in patients with diabetes and hypertension.

Methods

In this open-label, prospective, randomized study, patients with type 2 diabetes and hypertension with poor control of blood pressure by 40 mg/day telmisartan were randomly assigned into the telmisartan 80 mg/day (Tel80) group (dose increase from 40 to 80 mg/day) or the telmisartan 40 mg + amlodipine 5 mg (Tel40 + Aml5) group. Serum levels of HMW adiponectin and parameters of glucose and lipid metabolism were measured at baseline and end of 3-months of treatment.

Results

Although the antihypertensive effects of the two doses of telmisartan were similar, a significant increase in HMW adiponectin levels was noted only in the Tel80 group. The increase was evident particularly in a group of patients whose HMW adiponectin levels were less than 4.0 μg/dL. A significant improvement in homeostasis model assessment of insulin resistance (HOMA-IR), a measure of insulin resistance, was also observed in the Tel80 group only.

Conclusions

In diabetic patients with hypertension, high-dose telmisartan increased HMW adiponectin levels and improved insulin resistance through activation of PPAR-gamma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension. 2004;43:993–1002.

    Article  PubMed  CAS  Google Scholar 

  2. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054–2057.

    Article  PubMed  CAS  Google Scholar 

  3. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes. 2005;54:3442–3452.

    Article  PubMed  CAS  Google Scholar 

  4. Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens. 2007;20:431–436.

    Article  PubMed  CAS  Google Scholar 

  5. Fujimoto M, Masuzaki H, Tanaka T, et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004;576:492–497.

    Article  PubMed  CAS  Google Scholar 

  6. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol. 2000;40:1380–1390.

    PubMed  CAS  Google Scholar 

  7. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care. 2004;27:1015.

    Article  PubMed  Google Scholar 

  8. Fogari R, Zoppi A, Ferrari I, et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res. 2009;41:893–898.

    Article  PubMed  CAS  Google Scholar 

  9. Lida M, Ueda K, Okayama A, et al.; NIPPON DATA 80 Research Group. Impact of elevated blood pressure on mortality from all causes, cardiovascular disease, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese — Nippon data 80. J Hum Hypertens. 2003;17:851–857.

    Article  PubMed  Google Scholar 

  10. Blüher M, Brennan AM, Kelesidis T, et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007;30:280–285.

    Article  PubMed  Google Scholar 

  11. Seino Y, Nanjo K, Tajima N, et al.; Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010;1:212–228.

    Article  Google Scholar 

  12. Kumada M, Kihara S, Sumitsuji S, et al.; Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89.

    CAS  Google Scholar 

  13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.

    Article  PubMed  CAS  Google Scholar 

  14. Teramoto T, Sasaki J, Ueshima H, et al.; Japan Atherosclerosis Society Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14:155–158.

    Article  PubMed  CAS  Google Scholar 

  15. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25:841–848.

    Article  PubMed  CAS  Google Scholar 

  16. Ishii N, Matsumura T, Kinoshita H, et al. Nifedipine induces peroxisome proliferator-activated receptorgamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010;30:1598–1605.

    Article  PubMed  CAS  Google Scholar 

  17. Yamada S, Ano N, Toda K, et al. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res. 2008;31:601–606.

    Article  PubMed  CAS  Google Scholar 

  18. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43:1003–1010.

    Article  PubMed  CAS  Google Scholar 

  19. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens. 2004;22:1977–1982.

    Article  PubMed  CAS  Google Scholar 

  20. Janke J, Endeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002;51:1699–1707.

    Article  PubMed  CAS  Google Scholar 

  21. Ausk KJ, Boyko EJ, Ioannou GM. Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care. 2010;33:1179–1185.

    Article  CAS  Google Scholar 

  22. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003;9:406–416.

    PubMed  Google Scholar 

  23. White M, Racine N, Ducharme A, de Champlain J. Therapeutic potential of angiotensin II receptor antagonists. Expert Opin Investig Drugs. 2001;10:1687–1701.

    Article  PubMed  CAS  Google Scholar 

  24. Wakino S, Law RE, Hsueh WA. Vascular protective effects by activation of nuclear receptor PPAR gamma. J Diabetes Complications. 2002;16:46–49.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan

    Hiroko Mori, Yosuke Okada, Tadashi Arao, Keiko Nishida & Yoshiya Tanaka

Authors
  1. Hiroko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yosuke Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadashi Arao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keiko Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiya Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiya Tanaka.

Additional information

To view enhanced content go to www.advancesintherapy.com

WHO Clinical Trial #UMIN000004400.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mori, H., Okada, Y., Arao, T. et al. Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients. Adv Therapy 29, 635–644 (2012). https://doi.org/10.1007/s12325-012-0032-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-012-0032-x

Keywords

Search

Navigation